Shanghai Longjin Investment Co., Ltd. agreed to acquire 2.8490% stake in Wuhan Ruifu Medical Treatment Health Equity Investment Partnership Enterprise (Limited Partnership) from Zhejiang Longsheng Group Co.,Ltd (SHSE:600352) on April 14, 2023. Buyer will acquire 100% stake in Wuhan Ruifu Medical Treatment Health Equity Investment Partnership Enterprise for CNY 1 billion. Wuhan Ruifu Medical Treatment Health Equity Investment Partnership Enterprise has reported total assets of CNY 859.2157 million and net assets of CNY 847.071 million on September 30, 2022.

The board of Shandong Buchang Pharmaceuticals Co., Ltd. has approved the deal on April 14, 2023, and does not need the Shareholders' Approval.